MA53158A - Procédés de criblage et d'identification d'agents inhibant ou modulant le complexe de sortie nucléaire du virus de l'herpès - Google Patents

Procédés de criblage et d'identification d'agents inhibant ou modulant le complexe de sortie nucléaire du virus de l'herpès

Info

Publication number
MA53158A
MA53158A MA053158A MA53158A MA53158A MA 53158 A MA53158 A MA 53158A MA 053158 A MA053158 A MA 053158A MA 53158 A MA53158 A MA 53158A MA 53158 A MA53158 A MA 53158A
Authority
MA
Morocco
Prior art keywords
modulating
screening
methods
herpes virus
identifying agents
Prior art date
Application number
MA053158A
Other languages
English (en)
Inventor
Jutta Eichler
Manfred Marschall
Yves Muller
Heinrich Sticht
Original Assignee
Aicuris Gmbh & Co Kg
Univ Friedrich Alexander Er
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg, Univ Friedrich Alexander Er filed Critical Aicuris Gmbh & Co Kg
Publication of MA53158A publication Critical patent/MA53158A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/05—Epstein-Barr virus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA053158A 2018-07-20 2019-07-19 Procédés de criblage et d'identification d'agents inhibant ou modulant le complexe de sortie nucléaire du virus de l'herpès MA53158A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18184806 2018-07-20

Publications (1)

Publication Number Publication Date
MA53158A true MA53158A (fr) 2021-05-26

Family

ID=63014438

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053158A MA53158A (fr) 2018-07-20 2019-07-19 Procédés de criblage et d'identification d'agents inhibant ou modulant le complexe de sortie nucléaire du virus de l'herpès

Country Status (6)

Country Link
US (1) US20210396761A1 (fr)
EP (1) EP3823979A1 (fr)
AU (2) AU2019304526B2 (fr)
CA (1) CA3106833A1 (fr)
MA (1) MA53158A (fr)
WO (1) WO2020016433A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202220971A (zh) 2020-08-05 2022-06-01 德商百靈佳殷格翰國際股份有限公司 二氟甲基-吡啶-2-基三唑

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2097925T3 (es) 1991-09-18 1997-04-16 Affymax Tech Nv Metodo para sintetizar diversas colecciones de oligomeros.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
ES2204910T3 (es) 1992-10-01 2004-05-01 The Trustees Of Columbia University In The City Of New York Bibliotecas quimicas combinatorias complejas codificadas con señales.
EP0726906A4 (fr) 1993-11-02 1998-10-07 Affymax Tech Nv Synthetisation et criblage de diverses molecules
AU691296B2 (en) 1994-05-06 1998-05-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
WO2000029584A1 (fr) * 1998-11-18 2000-05-25 Genentech, Inc. Variants d'anticorps a affinite de liaison superieure par rapport aux anticorps d'origine
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US8501194B2 (en) * 2006-03-10 2013-08-06 The Regents Of The University Of California Vaccine for viruses that cause persistent or latent infections
EA201270662A1 (ru) * 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
CA2890061A1 (fr) * 2012-12-04 2014-06-12 Merck Sharp & Dohme Corp. Vecteurs viraux a replication conditionnelle
US20150051090A1 (en) * 2013-08-19 2015-02-19 D.E. Shaw Research, Llc Methods for in silico screening
JP2019512501A (ja) * 2016-03-14 2019-05-16 レッドバイオテック・アーゲーＲｅｄｂｉｏｔｅｃ Ａｇ Ｈｓｖを処置するための手段及び方法
JP2021519598A (ja) * 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性エプスタインバーウイルスポリペプチド

Also Published As

Publication number Publication date
US20210396761A1 (en) 2021-12-23
EP3823979A1 (fr) 2021-05-26
WO2020016433A1 (fr) 2020-01-23
AU2024216501A1 (en) 2024-09-19
CA3106833A1 (fr) 2020-01-23
AU2019304526A1 (en) 2020-12-24
AU2019304526B2 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
CO2019005842A2 (es) Anticuerpos anti-pd-l1 radiomarcados para imágenes de inmuno-pet
MA46200A (fr) Procédés d'utilisation d'un anticorps bispécifique qui reconnaît le facteur de coagulation ix et/ou le facteur de coagulation ix activé et le facteur de coagulation x et/ou le facteur de coagulation x activé
MA53235A (fr) Indoles substitués et procédés d'utilisation associés
MA46917A (fr) Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation
IL264104A (en) pd-l1 binding proteins and methods of using them
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
WO2016069591A3 (fr) Compositions, procédés et utilisation de criblage létal synthétique
MA45671A (fr) Anticorps antivirus zika et procédés d'utilisation
MA53919A (fr) Constructions d'acides nucléiques et procédés d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA56121A (fr) Procédés d'identification d'attributs de protéines thérapeutiques
MA52797A (fr) Inhibiteurs de masp -2 et procédés d'utilisation
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
MA44993A (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
MA52963A (fr) Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
WO2018022881A3 (fr) Procédés d'identification d'anticorps bloquant les récepteurs lilrb
MA46844A (fr) Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation
IL281014A (en) Detection and documentation of speeding violations
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA56455A (fr) Auto-injecteur et procédés d'utilisation associés
MA50196A (fr) Récipient d'approvisionnement de développateur et système d'approvisionnement de développateur
FR3049061B1 (fr) Dispositif d'analyse d'un echantillon biologique
MA52796A (fr) Compositions et procédés de détection d'une lésion cérébrale traumatique
MA56457A (fr) Modulateurs de hsd17b13 et leurs procédés d'utilisation